Form 4: CorMedix Director Gregory Scott Duncan Acquires 25,000 Restricted Stock Units

Director Gregory Scott Duncan of CorMedix Inc. was granted 25,000 restricted stock units on January 17, 2025, which will vest on January 17, 2026.

Summary

• Gregory Scott Duncan, a director at CorMedix Inc., acquired 25,000 restricted stock units on January 17, 2025.
• These restricted stock units were granted at a price of $0.00.
• Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock.
• The restricted stock units will vest in full on January 17, 2026, contingent upon continued service on the vesting date.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock units to a director, which is generally viewed positively for aligning interests. There are no negative implications.

Positives

• The grant of restricted stock units aligns the director's interests with the long-term performance of the company.
• The vesting period encourages continued service and commitment from the director.

Future Outlook

The restricted stock units will vest on January 17, 2026, subject to continued service.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Granting restricted stock units to directors is a common practice across the industry to incentivize performance and retention.
• The vesting period of one year is also a typical timeframe for such grants.

Stakeholder Impact

• The grant of restricted stock units aligns the director's interests with those of shareholders.
• The vesting period encourages continued service and commitment from the director, which can benefit the company and its stakeholders.

Key Dates

Keywords

restricted stock units, insider trading, stock grant, director, CorMedix, CRMD, equity